Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
06 mars 2024 01h30 HE
|
Transgene S.A.
Poster presentation of new data from ongoing randomized Phase I trial targeting head and neck cancers Strasbourg, France, March 6, 2024, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a...
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
05 mars 2024 16h45 HE
|
Prelude Therapeutics, Inc.
Prelude Therapeutics to present preclinical data posters at the 2024 AACR on its oral SMARCA2 degrader, CDK9 inhibitor and next-gen CDK4/6 inhibitor